Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Clinical trial NCT02188537 · COMPLETED
Trial details
- NCT number
- NCT02188537
- Sponsor
- Swiss Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-02
- Primary completion
- 2016-07-26
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.